FDA Approves First Absorbable Coronary Stent

Share this content:
FDA Approves First Absorbable Coronary Stent
FDA Approves First Absorbable Coronary Stent

TUESDAY, July 5, 2016 (HealthDay News) -- The first coronary stent to be gradually absorbed by the body has been approved by the U.S. Food and Drug Administration.

The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is absorbed within about three years, the agency said Tuesday in a news release. The stent also releases the drug everolimus to limit the growth of scar tissue.

The newly approved stent is made from a biodegradable polymer called poly(L-lactide), which is similar to materials used in other types of absorbable medical devices, the agency noted. In this case, the device's absorption rids the affected artery of foreign material once it's no longer necessary, the FDA said. Once the product disintegrates, four platinum markers are left to indicate where the stent had been implanted.

The product was evaluated in a clinical study involving 2,008 people. The major cardiac adverse event rate in the Absorb GT1 BVS group was 7.8 percent, which was deemed clinically comparable to the rate observed in the control group (6.1 percent). The rate of blood clots forming within the devices was 1.54 percent for the Absorb GT1 BVS and 0.74 percent for the control, according to the FDA.

The new stent is produced by Santa Clara, California-based Abbott Vascular.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »